Person Details

Anthony Manning,

Anthony Manning,, Ph.D., Chief Scientific Officer

Dr. Manning joined Momenta in January 2013. He is responsible for research and driving the discovery of novel products. Since joining Momenta, his teams have advanced three novel autoimmune drugs nipocalimab (M281), M230, and M254 into development and implemented a research engine to discover novel, first-in-class therapeutics for rare immune-related diseases. Prior to Momenta, Dr. Manning was Senior Vice President of Research and Preclinical Development at Aileron Therapeutics. Before that, he was Vice President and Head of Immunology Research for Biogen Idec, Inc. Before that, he was Vice President and Global Head of Inflammation, Autoimmunity and Transplantation Research at Roche Pharmaceuticals.